Chemoprevention in hereditary colorectal cancer syndromes

Cancer

Volumn 86, Issue 8 SUPPL., 1999, Pages 1731-1743

  Hawk, Ernest ^a,b   Lubet, Ron ^a   Limburg, Paul ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EPN   (United States)

Author keywords

Chemoprevention; Colorectal cancer; Familial adenomatous polyposis; Genetic; Hereditary nonpolyposis colorectal cancer; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; CALCIUM CARBONATE; CELECOXIB; DOCOSAHEXAENOIC ACID; EFLORNITHINE; FISH OIL; FLUOROURACIL; FLURBIPROFEN; FRUCTOSE OLIGOSACCHARIDE; INDOMETACIN; NIMESULIDE; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RAT;

EID: 0033569812     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19991015)86:8+<1731::aid-cncr12>3.0.co;2-u     Document Type: Conference Paper

References (111)

1. Kune GA. Hereditary. In: Causes and control of colorectal cancer: a model for cancer prevention. Kune GA, editor. Boston: Kluwer Academic Publishers, 1996:47-68.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Jagelman DG. Clinical management of familial adenomatous polyposis. Cancer Surv 1989;8:159-67.
5. Philips RKS, Spigelman AD, Thomson JP. Familial adenomatous polyposis and other polyposis syndromes. Boston: Edward Arnold, 1994.
6. Giardiello FM, Krush AJ, Petersen GM, Booker SV, Kerr M, Tong LL, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. Gastroenterology 1994;106:1542-7.
7. Kinzler KW, Vogelstein B. Colorectal tumors. In: The genetic basis of human cancer. Vogelstein B, Kinzler KW, editors. New York: McGraw-Hill, 1997:565-87.
8. Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S. Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1996;39:384-7.
9. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993;36:1059-62.
10. Nugent KP, Spigelman AD, Phillips RK. Risk of extracolonic cancer in familial adenomatous polyposis. Br J Surg 1996; 83:1121-2.
11. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34: 424-5.
12. Baba S. Hereditary nonpolyposis colorectal cancer: an update. Dis Colon Rectum 1997;40:S86-S95.
13. Boland CR. Hereditary nonpolyposis colorectal cancer. In: The genetic basis of human cancer. Vogelstein B, Kinzler KW, editors. New York: McGraw-Hill, 1997:333-46.
14. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-3.
15. Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996;28:479-82.
16. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-11.
17. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1-10.
18. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem 1996;S25:1-14.
19. Benner SE, Pajak TF, Lippman SM, Barley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86: 140-1.
20. Feinberg SM, Jagelman DG, Sarre RG, McGannon E, Fazio VW, Lavery IC, et al. Spontaneous resolution of rectal polyps in patients with familial polyposis following abdominal colectomy and ileorectal anastomosis. Dis Colon Rectum 1988; 31:169-75.
21. Miller HH, Bauman LJ, Friedman DR, DeCosse JJ. Psychosocial adjustment of familial polyposis patients and participation in a chemoprevention trial. Int J Psychiatry Med 1986;16:211-30.
22. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
23. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
24. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-8.
25. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 1995;92:4482-6.
26. Smits R, van der Houven van Oordt W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology 1998; 114:275-83.
27. Bilger A, Shoemaker AR, Gould KA, Dove WF. Manipulation of the mouse germline in the study of Min-induced neoplasia. Sem Cancer Biol 1996;7:249-60.
28. IARC Handbooks of Cancer Prevention. Non-steroidal anti-inflammatory drugs. ARC (Lyon), 1997:15-24.
29. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
30. Wechter WJ, Kantoci D, Murray EDJ, Quiggle DD, Leipold DD, Gibson KM, et al. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Mm)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997;57:4316-24.
31. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
32. Min/+ mouse with R-flurbiprofen (W-FB), and sulindac sulfone (SS) (abstract). Proc Am Assoc Cancer Res 1998;39:643.
33. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
34. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
35. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16-alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51:4528-34.
36. DeCosse JI, Adams MB, Kuzma JF, LoGerfo P, Condon RE. Effect of ascorbic acid on rectal polyps of patients with familial polyposis. Surgery 1975;78:608-12.
37. Watne AL, Lai HY, Carrier J, Coppula W. The diagnosis and surgical treatment of patients with Gardner's syndrome. Surgery 1977;82:327-33.
38. Bussey HJ, DeCosse JJ, Deschner EE, Eyers AA, Lesser ML, Morson BC, et al. A randomized trial of ascorbic acid in polyposis coli. Cancer 1982;50:1434-9.
39. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 1989;81:1290-7.
40. Greenberg ER, Baron JA, Tosteson TD, Freeman DHJ, Beck GJ, Bond JH, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994;331:141-7.
41. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, et al. Clinical development plan: calcium. J Cell Biochem 1994;820:86-109.
42. Lipkin M, Friedman E, Winawer SJ, Newmark H. Colonic epithelial cell proliferation in responders and nonresponders to supplemental dietary calcium. Cancer Res 1989; 49:248-54.
43. Thomas MG, Thomson JP, Williamson RC. Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis. Br J Surg 1993;80:499-501.
44. Stern HS, Gregoire RC, Kashtan H, Stadler J, Bruce RW. Long-term effects of dietary calcium on risk markers for colon cancer in patients with familial polyposis. Surgery 1990;108:528-33.
45. Itoh H, Iida M, Mibu R, Terasaka R, Ohsato K. Local chemotherapy for rectal polyposis: intraluminal administration of 5-fluorouracil for postoperative control of adenomas in the retained rectum in familial polyposis. J Clin Gastroenterol 1989;11:645-9.
46. Chameau J, D'Aubigny N, Burtin P, Person B, Boyer J. [Rectal micropolyps after total colectomy in familial polyposis. Efficacy of sulindac]. Micropolypes rectaux après colectomie totale pour polypose familiale. Efficacite du sulindac. Gastroenterol Clin Biol 1990;14:153-7.
47. Hial V, Horakova Z, Shaff FE, Beaven MA. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol 1976; 37:367-76.
48. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980;64:1323-7.
49. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
50. Gonzaga RA, Lima FR, Carneiro S, Maciel J, Amarante JM. Sulindac treatment for familial polyposis coli (letter). Lancet 1985;1:751.
51. Labayle C, Fischer D, Hagege JP. [Efficacy of sulindac in the treatment of rectocolic polyposis] (letter). Efficacite du sulindac dans le traitement de la polypose rectocolique. Gastroenterol Clin Biol 1986;10:436.
52. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
53. Friend WG. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am Fam Physician 1990;41:891-4.
54. Iwama T, Imajo M, Mishima Y. Is sulindac effective for familial adenomatous polyposis? Int J Colorectal Dis 1991;6: 235.
55. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
56. Parker AL, Kadakia SC, Maccini DM, Cassaday MA, Angueira CE. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993;88: 93-4.
57. Tonelli F, Valanzano R, Dolara P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig Dis 1994;12:259-64.
58. Labayle D, Boyer J, Drouhin F, Zarka Y, Fischer D. Sulindac in familial adenomatous polyposis. Lancet 1994;343: 417-8.
59. Muller A, Hurlimann R, Meyenberger C, Staub P, Kobler E, Ammann R. [Sulindac in familial adenomatous polyposis coli - preliminary findings of a prospective study]. Sulindac bei familiarer adenomatoser Polyposis coli - vorlaufige Daten einer prospektiven Studie. Schweiz Med Wochenschr 1994;124:651-4.
60. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994;106:362-6.
61. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac. Lancet 1994;343:180.
62. Giardiello FM, Offerhaus JA, Tersmette AC, Hylind LM, Krush AJ, Brensinger JD, et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578-81.
63. Hirata K, Itoh H, Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Report of two cases. Dis Colon Rectum 1994;37: 943-6.
64. Hirota C, Iida M, Aoyagi K, Matsumoto T, Tada S, Yao T, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996;78:1660-5.
65. van Stolk R, Beck GJ, Baron JA, Haile R, Summers R. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology 1998;115: 13-8.
66. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101: 635-9.
67. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
68. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998;43: 311-6.
69. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80:1618-9.
70. Nugent KP, Spigelman AD, Phillips RK. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum 1996;39:659-62.
71. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993;8:13-7.
72. Winde G, Schmid KW, Brandt B, Muller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997; 40:1156-68.
73. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995;38:813-30.
74. Giardiello FM. Gastrointestinal polyposis syndromes and hereditary nonpolyposis colorectal cancer. In: Gastrointestinal cancers: biology, diagnosis, and therapy. Rustgi AK, editor. Philadelphia: Lippincott-Raven Publishers, 1995: 367-77.
75. Bertoni G, Sassatelli R, Nigrisoli E, Pennazio M, Tansini P, Arrigoni A, et al. High prevalence of adenomas and microadenomas of the duodenal papilla and periampullary region in patients with familial adenomatous polyposis. Eur J Gastroenterol Hepatol 1996;8:1201-6.
76. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989;2:783-5.
77. Alexander JR, Andrews JM, Buchi KN, Lee RG, Becker JM, Burt RW. High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci 1989;34:167-70.
78. Sawada T, Muto T. Familial adenomatous polyposis: should patients undergo surveillance of the upper gastrointestinal tract? Endoscopy 1995;27:6-11.
79. Iida M, Yao T, Itoh H, Ohsato K, Watanabe H. Endoscopic features of adenoma of the duodenal papilla in familial polyposis of the colon. Gastrointest Endosc 1981;27:6-8.
80. Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RK, Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med 1994;87:704-6.
81. Kashiwagi H, Spigelman AD, Debinski HS, Talbot IC, Phillips RK. Surveillance of ampullary adenomas in familial adenomatous polyposis. Lancet 1994;344:1582.
82. Richard CS, Berk T, Bapat BV, Haber G, Cohen Z, Gallinger S. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis 1997;12:14-8.
83. Seow-Choen F, Vijayan V, Keng V. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg 1996;83:1763-6.
84. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Effect of sulindac on small polyps in familial adenomatous polyposis (letter). Lancet 1995;345:855-6.
85. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis [see comments]. Br J Surg 1996;83:1494-504.
86. Penna C, Tiret E, Parc R, Sfairi A, Kartheuser A, Hannoun L, et al. Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surgery 1993;177:263-8.
87. Reitmair AH, Cai JC, Bjerknes M, Redston M, Cheng H, Pind MT, et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 1996;56: 2922-6.
88. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997;91:467-77.
89. DeWind N, Dekker M, van Rossum A, van der Valk M, te RH. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res 1998;58:248-55.
90. Burt RW. Cohorts with familial disposition for colon cancers in chemoprevention trials. J Cell Biochem 1996;25S:131-5.
91. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995;75:936-8.
92. Cats A, Kleibeuker JH, van der Meer R, Kuipers F, Sluiter WJ, Hardonk MJ, et al. Randomized, double-blinded, placebo-controlled intervention study with supplemental calcium in families with hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 1995;87:598-603.
93. Lipkin M, Newmark H. Effect of added dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer. N Engl J Med 1985;313:1381-4.
94. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6: 105-10.
95. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-7.
96. Burn J, Chapman PD, Mathers J, Bertario L, Bishop DT, Bulow S, et al. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention. Eur J Cancer 1995;31A:1385-6.
97. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7.
98. Jacoby RF. The specific cyclooxygenase-2 inhibitor, celecoxib causes adenoma regression in the Apc mutant Min mouse, (abstract). Proc Am Assoc Cancer Res 1998;LB4-LB4.
99. Nakatsugi S, Fukutake M, Takahashi M, Fukuda K, Isoi T, Taniguchi Y, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997;88:1117-20.
100. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996;56: 710-4.
101. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996;17:1757-60.
102. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56:2556-60.
103. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996:87:803-9.
104. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/ + mice independent of prostaglandin biosynthesis. Cancer Res 1997;57: 4267-73.
105. Oshima M, Oshima H, Tsutsumi M, Nishimura S, Sugimura T, Nagao M, et al. Effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine on intestinal polyp development in Apc delta 716 knockout mice. Mol Carcinog 1996;15:11-7.
106. Kennedy AR, Beazer-Barclay Y, Kinzler KW, Newberne PM. Suppression of carcinogenesis in the intestines of Min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 1996;56:679-82.
107. Pierre F, Perrin P, Champ M, Bornet F, Meflah K, Menanteau J. Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice. Cancer Res 1997;57:225-8.
108. Oshima M, Takahashi M, Oshima H, Tsutsumi M, Yazawa K, Sugimura T, et al. Effects of docosahexaenoic acid (DHA) on intestinal polyp development in Apc delta 716 knockout mice. Carcinogenesis 1995;16:2605-7.
109. Paulsen JE, Stamm T, Alexander J. A fish oil-derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl esters inhibits the formation and growth of aberrant crypt foci in rat colon. Pharmacol Toxicol 1998;82: 28-33.
110. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis. Lancet 1993;342:1120.
111. van Stolk R, Budd GT, Hayton W, Elson P, Provencher K, Church JM, et al. Phase I trial of sulindac sulfone in patients with familial adenomatous polyposis (FAP) with rectal polyps: optimal dose and safety (abstract). Gasteroenterology 1997;112:A673.